

MAP Number: 2025-DK-MSP-00011
ODS/One Key ID Number:
Vendor Number:

DONATION AGREEMENT

Parties:

This Donation Agreement ("Agreement") is between

AbbVie AS,
Org. No: 998 085 497,
Martin Linges vei 25, 1364 FORNEBU, Norway
("AbbVie")

and

Health Care Organization or other Non-Profit Third-Party Organization ("Organization")	Scandinavian Educational Society for Dystonia and Spasticity Treatment (SKANDYSPAS)
Address	Østervej 26, 2750 Ballerup
Organizational number:	39433990

AbbVie and the Organization are collectively named the "Parties".

Background

AbbVie has decided to support the project described below (the "Project").

Short description of Project:	See appendix 1
-------------------------------	----------------

1. The Donation:

AbbVie hereby agrees to make the following donation to support the Project:

Description of the Donation: (monetary donation or donation of equipment/other in-kind donation)	See appendix 1. Note that AbbVie is not a member of the committee and has no influence over the diploma programme.
The monetary value of the donation:	30.000 DKK

Both parties understand and agree that the Donation is being made without any explicit or implicit intention to obtain or retain business between AbbVie and the Organization and/or AbbVie and a healthcare professional or other employee in the Organization (no quid pro quo).

MAP Number: 2025-DK-MSP-00011

ODS/One Key ID Number:

Vendor Number:

The donation does not constitute an incentive for the recommendation, prescription purchase, supply, sales or administration of a particular medicinal product.

The Donation is made by AbbVie to the benefit of the Organization. It does not, and is not intended to, constitute a personal benefit to any individual healthcare professional or other employee of the Organization.

In case of in-kind donation, AbbVie hereby effects the donation by transferring and providing without any consideration the legal title and possession to the donated equipment to the Organization. AbbVie will not be responsible for, and not compensate any costs in relation to, the servicing or the maintenance of the equipment.

2. Organization's Obligations

The Organization commits to carry out the Project as described above, only use the Donation for the purpose of carrying out the Project, and as soon as possible to AbbVie confirm that the Donation was used solely for the purpose of the Project.

The Organization further agrees that the Donation will not in any part be used for Organization's social or internal activities, or ordinary/daily activities. Moreover, if the Organization uses the Donation for other purposes than for the purpose of conducting the Project, AbbVie has the right to wholly or partly reclaim the Donation.

3. Transparency

There should be full transparency and disclosure of this Agreement according to the Code on Disclosure of Transfers of Value from Pharmaceutical Companies to Healthcare Professionals and Healthcare Organisations ("the EFPIA Disclosure Code").

The Organization shall transparently declare that AbbVie has provided the donation.

4. Compliance with Laws

The Organization represents and warrants that it is in compliance with, and undertakes that in its performance of its obligations under this Agreement it shall continue to comply with, all applicable laws and regulations, including applicable anti-corruption laws and the ethical rules of the pharmaceutical industry. The Organization further warrants that it, to the best of its knowledge, does not and will not engage any person or entity to perform services under this agreement who was convicted for any criminal offense, e.g. payment of illegal gratuities, fraud, false statement, blackmail, falsification or destruction of records.

5. Term

This agreement shall become effective on the date of signature by both parties. The agreement shall be valid until all obligations under the agreement have been fulfilled by the Parties, after which the agreement will automatically expire.

6. Entire Agreement

This Agreement constitutes the Parties' entire agreement on all issues which the Agreement relates to. Modifications of or additions to this Agreement need to be in writing and signed by authorized representatives of both Parties.

MAP Number: 2025-DK-MSP-00011
ODS/One Key ID Number:
Vendor Number:

7. Governing Law

Norwegian law shall be applicable to this Agreement.

Signatures:


Date
For AbbVie AS


[matthew illes \(13-Nov-2025 09:50:27 GMT+1\)](#)

Signature

General manager, Matthew Iles
Title and printed name

Date
Signed for SKANDYSPAS


[Bo Biering-Sørensen \(13-Nov-2025 22:19:00 GMT+1\)](#)

Signature

Chair, Bo Biering-Sørensen
Title and printed name

Appendix 1: Grant, Donations & Charitable Contributions Application Form:

Please note that Grants and Donations to Healthcare Organisations cannot be linked to the use of AbbVie products.

ORGANISATION

Name of Organization: Scandinavian Educational Society for Dystonia and Spasticity Treatment

Organization no:

Address: Østervej 26

Postal Code: 2750 Town/City: Ballerup

Telephone: +45 23836997 Email: jeanet.roger.vilhelmsen@regionh.dk

Briefly describe the nature of your Organization:

The purpose of the organization is as follows:

- Strengthen formalized education in the treatment of dystonia and spasticity.
- Enhance diagnosis, treatment, and research within the field of dystonia and spasticity. This shall be promoted through education and networking via educational forums.
- Promote interdisciplinary collaboration among all professional groups involved in the treatment of dystonia and spasticity.
- Support professional development both within individual disciplines and across disciplines.
- Facilitate the exchange of experience and knowledge between individual professional groups and across disciplines.
- Serve as a consultative and collaborative partner for relevant authorities.
- Increase general awareness and knowledge about dystonia and spasticity treatment.
- Create networks to promote multicenter research projects.

Name of individual submitting request (PRINT NAME)*:Bo Biering-Sørensen

Role: Chair

x Bo Biering-Sørensen _____ 22.10.2025 _____

Signature of representative from the Organization* Date:

* Person should be a representative who is permitted to submit this request on behalf of the organization requesting funding and should be prepared to respond to questions from and provide additional information from AbbVie Ltd.

For healthcare organizations this individual must be a health care professional.

GRANT/DONATION DETAILS

Total Amount Requested in (SEK): 44.000,00

Please describe your funding request:

SKANDYSPAS (www.skandyspas.com) requests a sponsorship/unrestricted grant to support the preparation and publication of a manuscript describing the SKANDYSPAS Diploma Education in dystonia and spasticity treatment.

Please explain why the funding needed?

SKANDYSPAS is responsible for the 1.5-year diploma programme in dystonia and spasticity treatment. It is the only formalized programme worldwide that teaches and trains participants in all aspects of dystonia, spasticity and sialorrhea through three three-day in-person courses and two webinars. Participating clinicians (neurologists, neuro-pediatricians, neurophysiologists and rehabilitation physicians) receive up to 15 hours of hands-on ultrasound-guided botulinum toxin training during the in-person courses. Trainees also complete two focused two-day visits at established centres, where they demonstrate application of learned theory in practice using ultrasound and EMG guidance. Education is concluded with an oral examination based on a video case from the participant's own practice. The programme graduated its first cohort in February 2017.

To promote the diploma and to inspire other countries to develop structured education that improves clinician competence and patient care in spasticity, dystonia and hypersalivation, we plan to publish an article describing the programme's purpose, development and structure. BMC Medical Education has invited us to submit a manuscript for the topic "Shaping the future of ultrasound education: advancing equity, innovation, and faculty development," and they have expressed interest in a SKANDYSPAS submission. The submission deadline is 27 February 2026.

All SKANDYSPAS board members are clinically very busy and have limited time to prepare the manuscript from scratch. We have therefore obtained a proposal from RX Communications for professional medical writing support to develop the first draft and assist through publication. The proposed fee for medical writing is £7,820 (GBP). Publication (article processing) fees are estimated at £2,390 (GBP). The total estimated cost is £10,210 (GBP), approximately 90,000 DKK.

We are requesting an unrestricted grant of 30,000 DKK from each of our three head sponsors (IPSEN, Merz, AbbVie) to cover these costs and enable timely submission and publication of this unique educational model.

Please describe how the funding will either advance medical education or science, or contribute to improvements in the quality of healthcare/patient care:

The publication will inspire other countries to develop structured education that improves clinician competence and patient care in spasticity, dystonia and hypersalivation

Please confirm that, if provided, funds will not result in any personal benefit or financial gain to you or any individual.

I confirm:

If the DONATION Request is in regards to donation of Fibroscans or Ultrasound equipment the following additional information is required:

Expected impact on patient care and time of this impact:

Number of Fibroscans / Ultrasound equipment already present in the same institution:

If other Fibroscans / Ultrasound Equipment give a clear explanation for the need of additional equipment at the requesting institution:

If other Fibroscans / Ultrasound equipment have already been transferred to the same institution, give a clear indication on the intended use and geographical area where additional equipment will be used:

FINANCIAL DECLARATION

Please note that in accordance with the requirements of the LIF Code of Practice for the Pharmaceutical Industry and EFPIA Disclosure Code, AbbVie AB is required to publicly disclose details of grants/donations to healthcare organisations (including the financial amount/value, and your healthcare organisation name as the recipient)